显著的粘膜脂质转移在治疗难治性炎症性肠病:一个脂质学研究
Øystein K Moe1,2,3, Qian Gao4, Dawei Geng4
1Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Oystein.Kittel.Moe@unn.no.
BMC gastroenterology
|May 20, 2025
概括
治疗不耐药的性结肠炎 (UC) 患者表现出膜脂质配置的改变,炎症和保护性脂质的减少. 炎症性肠病 (IBD) 患者的缓解反映了正常的脂质样本.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 在炎症性肠病 (IBD) 中对生物药物无反应的机制尚未完全理解.
- 具有足够药物水平的耐火性IBD患者的脂质样本的表征至关重要.
研究的目的:
- 为了研究和描述IBD耐生物治疗的患者的粘膜脂质概况.
- 为了比较耐药性IBD患者,先前未接受治疗的患者,缓解期患者和健康对照患者之间的脂质概况.
主要方法:
- 对IBD患者的粘膜活检进行了脂管学分析,这些患者对抗瘤坏死因子 (anti-TNF) 或vedolizumab耐药,并且来自参考组.
- 统计分析包括一般化的最小平方,log2转换,自动缩放和FDR的本杰明-霍赫伯格校正.
主要成果:
- 与未经治疗的UC患者相比,治疗耐药性性结肠炎 (UC) 患者的炎症性脂质 (胺,胺) 和保护性脂质 (甘油醇,甘油乙醇胺) 水平显著降低.
- 与对照组相比,耐火性UC患者显示了胺,胺,胺,胺,甘氨酸,甘氨酸,甘氨酸,甘氨酸和甘氨酸的重大变化.
- 与其他CD组相比,克罗恩氏病 (CD) 治疗不耐药的患者仅表现出轻微的脂质特征变化. 缓解期IBD患者的脂质状况与健康对照人群相似.
结论:
- 治疗耐药性UC的粘膜脂质概况明显改变,这表明与长期炎症相关的动态过程.
- 这些发现突出了潜在的基于脂质的生物标志物或耐火性IBD的治疗点.
- 在IBD缓解中恢复的粘膜脂质样本表明恢复到正常的生理状态.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
291
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
291
Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Lipid Digestion
90.1K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
90.1K
Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116


